Document:

Letter Agreement

 Exhibit 10.1 
 ViroPharma Incorporated 
 730 Stockton Drive 
 Exton, PA 19341 
 January 9, 2009 
 Robert Pietrusko 
 1103 Dickens Way 
 West Chester, PA 19380 
  

			
	Re:	  	Amendment to Outstanding Options

 Dear Bob: 
 In
connection with your continued employment as Vice President, Global Regulatory Affairs and Quality of ViroPharma Incorporated (the “Company”), the terms of the option agreements (collectively, the “Option Agreements”) granted to
you prior to the date of this letter provide that such Option Agreements may vest following a Change in Control (as defined in the relevant equity plan pursuant to which an option agreement was issued) if certain conditions are met. As a recognition
of your continuing service to the Company, the Company hereby amends the Option Agreements listed on Schedule A hereto (the “Amended Options”) to add the following vesting conditions relating to a Change in Control: 
  

	 	16.	Change of Control Vesting Conditions. 

 (a) Discontinuation of Plan and Non-Substitution of Shares. Notwithstanding anything to the contrary set forth in the Plan other than Section 14.4 or Section 14.5, if there is a Change of Control prior to the date that the
Optionee’s employment with the Company has ceased for any reason and in which the Plan is not continued by a successor corporation, and in which equivalent, substituted options for common stock and substituted restricted shares in a successor
corporation are not provided to the Optionee, then, all of the Optionee’s unvested Shares hereunder shall be fully and immediately vested and exercisable. 
 (b) Continuation of Plan or Substitution of Shares. If there is a Change of Control prior to the date that the Optionee’s
employment with the Company has ceased for any reason and in which the Plan is continued by a successor corporation or in which equivalent substituted options for common stock and substituted restricted shares in a successor corporation are provided
to the Optionee, any then unvested Shares under this Option shall vest as follows: 
 (i) if the Optionee is not offered
substantially equivalent employment or service with the successor corporation or a related employer (both in terms of duties and compensation), then any unvested portion of this Option as of the date of the Change of Control shall be fully and
immediately vested and exercisable and shall have restrictions lifted; and 

 (ii) if the Optionee is offered substantially equivalent employment with the successor
corporation or a related employer (both in terms of duties and compensation), then any then unvested Shares under this Option shall not be subject to accelerated vesting; provided however, that if the Optionee’s employment with the successor
corporation or related employer is terminated by the successor corporation or related employer during the six month period following such Change of Control, then any unvested Shares under this Option or substituted options or restricted shares shall
be fully and immediately vested and exercisable at the date of the Optionee’s termination of employment. 
 (c)
Notwithstanding Sections 16(a) and 16(b) hereof, the Optionee shall be notified by the Board or the Committee of any event that may constitute a Change of Control in advance of the effective date of such Change of Control. Notice shall be provided,
in the sole discretion of the Committee, as soon as reasonably practicable before the Change of Control. The Optionee may refuse to accept accelerated vesting of his Award after consideration of the tax consequences to such Optionee resulting from
the Change of Control, provided that any such refusal shall be communicated to the Committee in writing before the Change of Control. If it is not practicable to provide advance notice of such Change of Control, the Optionee will be deemed to have
elected to refuse such acceleration, but only to the extent that it is determined, as soon as practicable after the Change of Control, that accelerated vesting will result in negative tax consequences under Section 280G of the Code. 

provided however; that, except for renumbering any relevant paragraphs or cross-references set forth within of the Options Agreements (each as determined by
the Board, in its sole discretion), the term set forth in each Amended Option shall remain in effect and shall not be modified. 

 Thank you for your continued service to the Company. 
  

	
	Very truly yours,
	
	 /s/ Vincent J. Milano

	Vincent J. Milano

 Agreed and Acknowledged: 
  

	
	 /s/ Robert Pietrusko

	Robert Pietrusko

 Schedule A 
 Incentive Stock Options 
  

										
	 Grant Date
	  	Options
Granted	  	Price	  	Vested	  	Unvested
	 4/30/2007
	  	26,524	  	$	15.08	  	6,631	  	19,893
	 1/11/2008
	  	5,000	  	$	9.96	  		  	5,000
	 6/13/2008
	  	5,025	  	$	9.99	  		  	5,025
	 1/8/2009
	  	7,407	  	$	13.50	  	0	  	7,407
	 TOTAL
	  	43,956	  			  	6,631	  	37,325

 Non-qualified Stock Options 
  

										
	 Grant Date
	  	Options
Granted	  	Price	  	Vested	  	Unvested
	 4/30/2007
	  	73,476	  	$	15.08	  	18,369	  	55,107
	 6/15/2007
	  	14,000	  	$	13.97	  	3,500	  	10,500
	 1/11/2008
	  	15,000	  	$	9.96	  	0	  	15,000
	 6/13/2008
	  	49,975	  	$	9.99	  	0	  	49,975
	 1/8/2009
	  	52,593	  	$	13.50	  	0	  	52,593
	 TOTAL
	  	205,044	  			  	21,869	  	183,175ViroPharma U.S. Cash Bonus Plan

 Exhibit 10.2 
 ViroPharma U.S. Cash Bonus Plan 
 The ViroPharma Incorporated Cash Bonus Plan applies to each of our employees,
including the members of our management team. Each employee receives a target bonus, expressed as a percentage of his or her base salary for the year. The amount of a specific employee’s target bonus varies by the employee’s role in the
company and his or her applicable pay band, as identified in the table below: 
 Exempt Positions 
  

									
	 Position 
	  	Pay Band(s)	  	Target	 	 	Maximum	 
	CEO	  	18	  	50	%	 	62.5	%
	Management Team	  	17	  	50	%	 	62.5	%
	Vice President	  	16B	  	40	%	 	50 	%
	Vice President	  	16A	  	30	%	 	37.5	%
	Senior Director	  	15B	  	30	%	 	37.5	%
	Director	  	15A	  	20	%	 	25 	%
	Associate Director	  	14	  	20	%	 	25 	%
	Assistant Director	  	13B	  	20	%	 	25 	%
	Manager	  	13A	  	15	%	 	18.75	%
	Senior Professional	  	12	  	15	%	 	18.75	%
	Senior Professional	  	11	  	12	%	 	15 	%
	Mid-level Professional	  	10	  	12	%	 	15	%
	Professional	  	9	  	12	%	 	15 	%
	Entry Level	  	7-8	  	10	%	 	12.5	%

 Non-Exempt Positions 
  

									
	Senior Non-Exempt	  	6	  	10	%	  	12.5	%
	Non-Exempt	  	5	  	10	%	  	12.5	%
	Non-Exempt	  	2-4	  	8	%	  	10	%
	Non-Exempt	  	1	  	6	%	  	7.5	%

 For employees with less than one year of service, the bonus will be pro-rated based on the actual base pay
earnings during the bonus year. Overtime earnings are not eligible to be included in bonus calculations. 
 Awards pursuant to the plan are based upon two
factors: Company and Individual. The Company factor represents the degree to which we achieved our overall corporate goals in a given year. Each employee also is given an Individual factor by his or her supervisor to reflect the employee’s
performance against his or her individual goals for the year. Each factor can be assigned a value of up to 125% for maximum performance. Thus, depending on the performance of the company and the individual employee, an employee may receive up to
125% of his or her target bonus. 
 Each of the Company and Individual factors is itself separately weighted for each employee. The weighting assigned to
each factor varies by employee depending on the role he or she plays with the company and his or her applicable pay band. For example, for the members of the company’s management team, the Company factor is weighted significantly higher than
the Individual factor in order to ensure that the bonus system for the company’s management team is closely tied to the company’s performance. 

 The weighting of the factors is as follows: 
  

							
	 Exempt Positions
	  	Company Factor	 	 	Individual Factor	 
	 Pay Bands 17, 18
	  	70	%	 	30	%
	 Pay Bands 15A, 15B, 16A, 16B
	  	60	%	 	40	%
	 All others
	  	50	%	 	50	%

 To determine the actual bonus paid, an employee’s target payout percentage is multiplied by the sum of the
Company factor plus the Individual factor as each is weighted for such employee. The result of that calculation is then multiplied by the employee’s target bonus. 
 Whether or not a bonus is actually paid, however, is ultimately at the discretion of the Compensation Committee of the Board of Directors. Bonuses, if any, are paid during the first quarter of the year immediately
following the year being measured.ViroPharma Board Compensation Policy

 Exhibit 10.3 
 ViroPharma Board Compensation Policy 
 Directors that are non-executive officers of ViroPharma, and directors that
are not affiliated with a person or entity that has been granted a contractual right to appoint a director to the Board of Directors (“Eligible Directors”), shall receive a cash retainer of $15,000 annually. The Chairman of the Board, if
an independent director as set forth in requirements of the Nasdaq Stock Market, shall receive an additional annual retainer of $30,000. A lead independent director shall receive an additional annual retainer of $10,000. The Audit Committee Chairman
shall receive an additional annual retainer of $5,000. The Compensation Committee Chairman and Nominating and Governance Committee Chairman shall receive an additional annual retainer of $3,500. Eligible Directors shall receive $2,500 for each board
meeting attended, provided that no payments shall be made for teleconferences lasting less than one (1) hour, and $1,000 for each committee meeting, plus travel expenses, for each board and committee meeting that they attend. 
 Eligible Directors shall receive an option grant of 25,000 shares, vesting in equal increments over 3 years, upon his or her initial election to the Board. These
directors also shall receive option grants once each year to purchase 10,000 shares of our common stock, vesting in full after one year from the date of grant. In a director’s initial year of service, he or she will be entitled to receive
(1) the 25,000 share initial election grant, and (2) a pro-rata portion of the 10,000 share annual grant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]